Cisatracurium besylate
CAS No. 96946-42-8
Cisatracurium besylate( —— )
Catalog No. M16875 CAS No. 96946-42-8
Cisatracurium Besylate is a nondepolarizing skeletal muscle relaxant for intravenous administration.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 52 | In Stock |
|
| 10MG | 37 | In Stock |
|
| 25MG | 61 | In Stock |
|
| 50MG | 105 | In Stock |
|
| 100MG | 176 | In Stock |
|
| 200MG | 259 | In Stock |
|
| 500MG | 442 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCisatracurium besylate
-
NoteResearch use only, not for human use.
-
Brief DescriptionCisatracurium Besylate is a nondepolarizing skeletal muscle relaxant for intravenous administration.
-
DescriptionCisatracurium Besylate is a nondepolarizing skeletal muscle relaxant for intravenous administration. Cisatracurium Besylate acts on cholinergic receptors, blocking neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors such as neostigmine. The neuromuscular block produced by cisatracurium besylate is readily antagonized by anticholinesterase agents once recovery has started. As with other nondepolarizing neuromuscular blocking agents, the more profound the neuromuscular block at the time of reversal, the longer the time required for recovery of neuromuscular function. Compared to other neuromuscular blocking agents, it is intermediate in its onset and duration of action. (In Vitro):Cisatracurium Besylate (51W89) is a neuromuscular-blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. It is a bisbenzyltetrahydroisoquinolinium agent with an intermediate duration of action. Cisatracurium Besylate (51W89) is one of the ten isomers of the parent molecule, atracurium. Moreover, cisatracurium represents approximately 15% of the atracurium mixture.
-
In VitroCisatracurium Besylate (51W89) is a neuromuscular-blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. It is a bisbenzyltetrahydroisoquinolinium agent with an intermediate duration of action. Cisatracurium Besylate (51W89) is one of the ten isomers of the parent molecule, atracurium. Moreover, cisatracurium represents approximately 15% of the atracurium mixture.
-
In Vivo——
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
TargetAChR
-
RecptorAChR| Adrenergic Receptor
-
Research AreaNeurological Disease
-
Indication——
Chemical Information
-
CAS Number96946-42-8
-
Formula Weight1243.48
-
Molecular FormulaC53H72N2O12·2C6H5O3S
-
Purity>98% (HPLC)
-
SolubilityEthanol: 249 mg/mL (200.24 mM); Water: 47 mg/mL (37.79 mM); DMSO: 249 mg/mL (200.24 mM)
-
SMILESC[N@@+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N@+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C=C6)OC)OC)OC)OC)C.C1=CC=C(C=C1)S(=O)(=O)[O-].C1=CC=C(C=C1)S(=O)(=O)[O-]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Dieye E, et al. Ann Intensive Care. 2014 Feb 11;4(1):3.
molnova catalog
related products
-
Pirenzepine dihydroc...
An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function.
-
Acetamiprid
Acetamiprid is a nicotinic acetylcholine receptor (nAChR) agonist. Acetamiprid is a neonicotinoid insecticide used worldwide. It is shown to be associated with neuromuscular and reproductive disorders. Acetamiprid decreases in body weight and mildly affected spermatogenesis.
-
Neoeriocitrin
Neoeriocitrin is a natural product isolated from Drynaria Rhizome, shows activity on proliferation and osteogenic differentiation in MC3T3-E1.?
Cart
sales@molnova.com